XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
A
A

Amgen

News

Reuters - 5 days ago

Amgen must face lawsuit claiming it hid $10.7 billion tax bill

UPDATE 1-Amgen must face lawsuit claiming it hid $10.7 billion tax bill Adds details from decision, case citation, byline By Jonathan Stempel NEW YORK, Sept 30 (Reuters) - A federal judge said Amgen AMGN.O must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders it might owe the Internal Revenue Service $10.7 billion for underreporting six years of taxes.
A
Reuters - 5 days ago

Amgen must face lawsuit claiming it hid $10.7 billion tax bill

Amgen must face lawsuit claiming it hid $10.7 billion tax bill NEW YORK, Sept 30 (Reuters) - A federal judge said Amgen AMGN.O must face a proposed class action accusing the drugmaker of waiting too long to tell shareholders it might owe the Internal Revenue Service $10.7 billion in taxes and penalties. U.S. District Judge John Cronan in Manhattan ruled on Monday that shareholders plausibly alleged they were misled by Amgen's concealing the true extent of its potential liability, and that the om
A
Reuters - 5 days ago

U.S. stocks weekly: Streaking in September

RPT-BUZZ-U.S. stocks weekly: Streaking in September Repeats from Friday with no changes to text. Updates chart ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fl
A
C
M
R
V
L
W
U
U
Reuters - 1 week ago

U.S. stocks weekly: Streaking in September

BUZZ-U.S. stocks weekly: Streaking in September ** S&P 500 .SPX extends winning streak to three weeks, adds 0.6% amid tame inflation data and China stimulus boost .N ** SPX on pace for monthly gain, take that September! ** Dow .DJI and Nasdaq .IXIC also up three consecutive weeks, though the latter still lined up at the velvet rope ** This as benchmark Treasury yield perks up , but can't hold 3-week highs after PCE ** Most sectors fleet of foot: Materials sprint to front of the pack, while Energ
A
C
M
R
V
L
W
U
U
Reuters - 1 week ago

Dow closes at record high as tame inflation report also lifts small caps

US STOCKS-Dow closes at record high as tame inflation report also lifts small caps U.S. PCE stands at 2.2% in Aug Russell 2000 index up 0.67% Bristol-Myers gains after schizophrenia drug approval Costco slips after Q4 revenue misses estimates Indexes: Dow up 0.33%, S&P 500 down 0.13%, Nasdaq down 0.39% Updates with 4:23 pm ET By Echo Wang Sept 27 (Reuters) - T he blue-chip Dow Jones Industrial Average closed at a record high as a subdued inflation report stoked hopes for more Federal Reserve rat
A
A
C
C
N
N
U
U
Reuters - 1 week ago

Dow closes at record high on tame inflation report that also boosts small caps

US STOCKS-Dow closes at record high on tame inflation report that also boosts small caps U.S. PCE stands at 2.2% in Aug Russell 2000 index up 1.5% Bristol-Myers gains after schizophrenia drug approval Costco slips after Q4 revenue misses estimates Indexes: Dow up, S&P 500 down, Nasdaq down Updates to 4:00 PM ET By Echo Wang Sept 27 (Reuters) - The blue-chip Dow Jones Industrial Average closed at a record high on Friday as investors welcomed a subdued inflation report that also lifted small -cap
A
A
C
C
N
N
U
U
Reuters - 1 week ago

Dow hits record high on tame inflation report that also boosts small caps

US STOCKS-Dow hits record high on tame inflation report that also boosts small caps U.S. PCE stands at 2.2% in Aug Russell 2000 index up 1.5% Bristol-Myers gains after schizophrenia drug approval Costco slips after Q4 revenue misses estimates Indexes: Dow up 0.45%, S&P 500 down 0.06%, Nasdaq down 0.32% Updates to 2:21 p.m. By Echo Wang Sept 27 (Reuters) - The blue-chip Dow Jones Industrial Average hit a new record high on Friday as investors cheered a tame inflation report that also boosted smal
A
A
C
C
N
N
U
U
Reuters - 1 week ago

S&P 500, Dow close lower as investors await insights on Fed rates, data

US STOCKS-S&P 500, Dow close lower as investors await insights on Fed rates, data KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Indexes: Dow down 0.70%, S&P 500 down 0.19%, Nasdaq up 0.04% Updates with closing prices By Echo Wang Sept 25 (Reuters) - The Dow Jones Industrial Average and S&P 500 closed lower on Wednesday, pulling back from recent record highs driven by China's sweeping stimulus packa
A
A
C
N
U
U
Reuters - 1 week ago

S&P 500, Dow end lower as investors await clues on Fed rates, data

US STOCKS-S&P 500, Dow end lower as investors await clues on Fed rates, data KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Dow weighed down by decline Amgen Updates with closing details By Echo Wang Sept 25 (Reuters) - The Dow Jones Industrial Average and S&P 500 closed lower on Wednesday, retreating from recent record highs fueled by China's sweeping stimulus package , as investors awaited further
A
A
C
N
U
U
Reuters - 1 week ago

Argenx tops BEL 20 index, broker points to positive Vyvgart momentum

BUZZ-Argenx tops BEL 20 index, broker points to positive Vyvgart momentum Updates with U.S. listed shares ** Shares of Belgian biotech company Argenx ARGX.BR closed 3.5 % higher at 485.10 euros, on Wednesday ** Stock topped Belgium's blue-chip BEL 20 index .BFX * * A nalysts at brokerage KBC Securities s ay c ompany's drug Vyvgart is still the top
A
Reuters - 1 week ago

S&P 500, Dow retreat as investors await clues on Fed rates, data

US STOCKS-S&P 500, Dow retreat as investors await clues on Fed rates, data KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Indexes: Dow down 0.63%, S&P 500 down 0.18%, Nasdaq up 0.03% Updates prices, details throughout By Echo Wang Sept 25 (Reuters) - The Dow Jones Industrial Average and S&P 500 edged lower on Wednesday, pulling back from recent record highs spurred by China's sweeping stimulus packa
A
A
C
N
U
U
Reuters - 1 week ago

U.S. STOCKS SLM Corp, Amgen Inc, Cintas Corp

BUZZ-U.S. STOCKS ON THE MOVE-SLM Corp, Amgen Inc, Cintas Corp Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were mixed on Wednesday, with the S&P 500 hovering near a record high, as investors awaited more indicators on the state of the economy and upcoming interest rate reductions.
A
A
A
C
C
H
M
N
S
F
U
U
G
Reuters - 1 week ago

Wall Street mixed as investors await Fed rate clues, data

US STOCKS-Wall Street mixed as investors await Fed rate clues, data For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. KB Home falls after Q3 profit misses estimates Apple edges down as data shows China sales drop in Aug Ford, GM slide on Morgan Stanley downgrade Indexes: Dow down 0.48%, S&P 500 flat, Nasdaq up 0.26% Updated at 11:42 a.m.
A
A
C
N
U
U
Reuters - 1 week ago

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Constellation Energy Corp CEG.OQ +4.2% Intel Corp INTC.OQ +3.4% NVIDIA Corp NVDA.OQ +2.2% Arm Holdings PLC ARM.OQ +2.2% Advanced Micro Devices Inc AMD.OQ +2.0% Bottom Performers Percent Change Amgen Inc AMGN.OQ -4.7% Diamondback Energy Inc FANG.OQ -2.1% Charter Communications Inc CHTR.OQ -1.9% CoStar Group Inc CSGP.OQ -1.9% Dexcom Inc DXCM.OQ -1.7% The Nasdaq 100 .NDX gained 31.72
A
C
I
N
A
U
D
D
C
Reuters - 1 week ago

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change Vistra Corp VST.N +6.8% Hewlett Packard Enterprise Co HPE.N +4.9% Constellation Energy Corp CEG.OQ +4.4% Intel Corp INTC.OQ +3.2% NVIDIA Corp NVDA.OQ +2.3% Bottom Performers Percent Change General Motors Co GM.N -5.4% Global Payments I
A
I
N
U
G
Reuters - 1 week ago

Amgen falls after reporting mixed data on two drugs

BUZZ-Amgen falls after reporting mixed data on two drugs ** Shares of Amgen AMGN.O fall as much as 4.4% to a near two-month low of $316.22 ** Stock is set for its worst day in nearly two months if losses hold ** Late on Tuesday drugmaker said its drugs Uplizna and rocatinlimab, for a rare muscular disorder and a skin disease, respectively, met the
A
R
S
Reuters - 1 week ago

Street View: Amgen's mixed data on two drugs fans competition concerns

BUZZ-Street View: Amgen's mixed data on two drugs fans competition concerns ** Amgen's AMGN.O drugs, Uplizna and rocatinlimab, for a rare muscular disorder and for a skin disease, respectively, met the main goals in their late-stage studies ** However, results from its drug rocatinlimab for treating atopic dermatitis or eczema, fell short of its co
A
Reuters - 1 week ago

ArgenX tops BEL 20 index, broker points to positive Vyvgart momentum

BUZZ-ArgenX tops BEL 20 index, broker points to positive Vyvgart momentum ** Shares in Belgian biotech company Argenx ARGX.BR rise 4%, with KBC analysts saying its Vyvgart drug is still the top contender despite positive trial data from a competitor ** Amgen AMGN.O on Tuesday reported favourable phase 3 data for its Uplizna drug in treating rare muscle-weakening disease myasthenia gravis ** "We deem the Uplizna dataset to be strong yet somewhat less compelling than Vyvgart," KBC says ** "Vyvgart
A
Reuters - 2 weeks ago

Amgen's muscular disorder drug meets main goal in late-stage study

UPDATE 4-Amgen's muscular disorder drug meets main goal in late-stage study Amgen's Uplizna succeeds in study for muscle-weakening Analysts say data from another experimental drug not 'competitive' Shares fall 2% in extended trading on mixed datasets Adds analyst comments in paragraphs 4, 10 and 11, trial data in paragraph 3, 8 and 9, exec comment in paragraph 6 By Bhanvi Satija and Puyaan Singh Sept 24 (Reuters) - Amgen AMGN.O said on Tuesday that its drug helped improve daily activities includ
A
A
R
S
Reuters - 2 weeks ago

Amgen's experimental skin disease drug meets main goals in study

Amgen's experimental skin disease drug meets main goals in study Sept 24 (Reuters) - Amgen AMGN.O said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment for an inflammatory skin condition known as atopic dermatitis. Reporting by Bhanvi Satija and Puyaan Singh in Bengaluru; Editing by
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.